Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.

You may also be interested in...



Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease

The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.

Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone

Eli Lilly is rumored to be the mystery bidder for ImClone - the latest wrinkle in an ongoing saga that pits the biotech's Chairman Carl Icahn against its marketing partner Bristol-Myers Squibb. Lilly is reportedly offering $6.1 billion for the biotech, or $70 a share, which, if true, validates Icahn's hard-line rejection of a standing offer from BMS to pay $62 a share

Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone

Eli Lilly is rumored to be the mystery bidder for ImClone - the latest wrinkle in an ongoing saga that pits the biotech's Chairman Carl Icahn against its marketing partner Bristol-Myers Squibb. Lilly is reportedly offering $6.1 billion for the biotech, or $70 a share, which, if true, validates Icahn's hard-line rejection of a standing offer from BMS to pay $62 a share

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel